COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS IN COLOMBIA

被引：0
|
作者：
Lasalvia, P. [1 ]
Rosselli, D. [2 ]
Castaneda-Cardona, C. [1 ]
Garzon, J. [3 ]
Hernandez, F. [1 ]
Beltran, C. [4 ]
Rojas, M. [4 ]
Lopez, M. C. [5 ]
Sarpong, E. M. [6 ]
机构：
[1] NeuroEconomix, Bogota, Colombia
[2] Pontificia Univ Javeriana, Bogota, Colombia
[3] Hosp San Ignacio, Bogota, Colombia
[4] Merck Sharp & Dohme Ltd, Bogota, Colombia
[5] Merck Sharp & Dhome, Bogota, Colombia
[6] MERCK & CO Inc, Rabway, NJ USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN35
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario
    Perrault, Louise
    Dahan, Sybil
    Iliza, Ange Christelle
    LeLorier, Jacques
    Zhanel, George G.
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2017, 2017
  • [32] A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections
    Saeed, Muhammad Waqas
    Gillani, Syed Wasif
    Mahmood, Rana Kamran
    Vippadapu, Prasanna
    Hussain, Mian Waqar
    Rathore, Hassaan Anwer
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [33] Cost-Effectiveness Evaluation of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections Accounting for Antibiotic Resistance
    Jansen, Jeroen P.
    Kumar, Ritesh
    Carmeli, Yehuda
    VALUE IN HEALTH, 2009, 12 (02) : 234 - 244
  • [34] Cost-effectiveness analysis of the treatment of urinary tract infections in a college-age population
    Kachur, SG
    Hiendlmayr, K
    VALUE IN HEALTH, 2004, 7 (03) : 365 - 365
  • [35] Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
    Goodlet, Kellie J.
    Nicolau, David P.
    Nailor, Michael D.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1811 - 1826
  • [36] Empiric treatment of uncomplicated urinary tract infections
    Preston, SL
    Abdel-Rahman, SM
    Nahata, MC
    ANNALS OF PHARMACOTHERAPY, 1998, 32 (11) : 1231 - 1233
  • [37] Therapy of complicated urinary tract infections
    Naber, KG
    Witte, W
    Bauernfeind, A
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1996, 25 (11) : 567 - 571
  • [38] The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection
    Arakawa, Soichi
    Kawahara, Kazuya
    Kawahara, Motoshi
    Yasuda, Mitsuru
    Fujimoto, Go
    Sato, Asako
    Yokokawa, Ruriko
    Yoshinari, Tomoko
    Rhee, Elizabeth G.
    Aoyama, Norihiro
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2019, 25 (02) : 104 - 110
  • [39] Cost-effectiveness of empiric PPI therapy in the treatment of laryngopharyngeal reflux symptoms
    Lee, Robert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S389 - S390
  • [40] Treatment efficacy and superinfection rates in complicated urinary tract infections treated with ertapenem or piperacillin tazobactam
    Dizbay, Murat
    Ozger, Hasan Selcuk
    Karasahin, Omer
    Karasahin, Emine Fusun
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (06) : 1760 - 1764
12345